Coherence Neuro

Based in California, Coherence Neuro specializes in advanced therapeutic neurotechnology, focusing on innovative solutions for cancer management through its proprietary brain-computer interface, SOMA. Coherence Neuro, founded in 2022 in San Francisco, US, develops neurotechnological solutions aimed at managing cancer treatment effectively. In November 2025, Coherence Neuro raised USD 10 million in seed funding co-led by new investor Artesian and Topology Ventures, with participation from other returning investors Blackbird Ventures, Possible Ventures, XEIA Venture Partners, Jumpspace Ventures, Divergent Capital, SmartGateVC, Spacewalk VC and Xtal. Individual investor also participated in this round.

Ben Woodington (CEO) and Elise Jenkins co-founded the firm. Coherence specializes in advanced therapeutic neurotechnology, primarily through its flagship product, SOMA, a therapeutic brain-computer interface designed to monitor and manage cancer treatment continuously. SOMA operates by administering custom bioelectronic stimulation tailored to the unique physiological characteristics of each patient, aiming to keep cancer in check on a 24/7 basis. The system includes a discreet wireless implant, a minimalist wearable device, and a companion app that delivers real-time insights and symptom tracking.

This innovative approach addresses the critical need for personalized, targeted cancer therapies, directly impacting patients’ quality of life by allowing them to manage their treatment discreetly and effectively. Coherence's products are particularly targeted toward oncology patients and healthcare providers seeking to integrate cutting-edge neurotechnological solutions into their treatment plans, with potential markets spanning North America, Europe, and parts of Asia. Coherence generates revenue through the commercialization of its SOMA system, which is structured around direct-to-consumer sales and partnerships with healthcare providers. The company’s business model includes subscription services for ongoing software updates and patient support, ensuring that users receive the latest advancements and personalized care.

Revenue transactions involve the sale of the SOMA implant, wearable device, and app, with potential bundled pricing options that encourage comprehensive adoption of the entire system. The firm targets both individual patients and institutional healthcare settings, positioning its services as critical components in modern cancer management strategies. Specific pricing structures for these innovative products reflect their unique therapeutic value and the personalization of treatment they offer. Coherence Neuro plans to leverage its recent funding of USD 10.

00 mn from investors like Artesian to enhance its product development, including upcoming iterations of the SOMA system which aim to improve user interface and effectiveness of cancer management. The firm intends to expand its market reach into Europe and parts of Asia by 2025, establishing partnerships with local healthcare providers to facilitate the adoption of its technology. Additionally, the funding will support efforts to enhance its marketing strategies and operational capabilities to cater to a growing patient base.